Sleep Disorder Market size was valued at USD 27.63 Billion in 2024 and is anticipated to reach USD 60.23 Billion by 2032, at a CAGR of 10.23% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Sleep Disorder Market Size 2024
USD 27.63 Billion
Sleep Disorder Market, CAGR
10.23%
Sleep Disorder Market Size 2032
USD 60.23 Billion
The Sleep Disorder Market is led by prominent players such as ResMed, Koninklijke Philips N.V., Fisher & Paykel Healthcare, Oura Health, and Fitbit I. These companies dominate through advanced product portfolios in sleep diagnostics, monitoring devices, and therapeutic solutions. Their focus on AI-enabled technologies, wearable innovations, and digital health integration strengthens their market presence. Strategic collaborations and global distribution networks further enhance competitiveness. Regionally, North America leads the market with a 41.2% share in 2024, supported by high awareness, advanced healthcare infrastructure, and strong adoption of sleep therapy devices across both clinical and homecare settings.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Sleep Disorder Market was valued at USD 27.63 Billion in 2024 and is projected to reach USD 60.23 Billion by 2032, growing at a CAGR of 10.23%.
Rising cases of insomnia and sleep apnea, along with increasing awareness of sleep health, are driving global demand for diagnostics and therapeutic devices.
Growing adoption of AI-based wearables, home sleep testing systems, and digital monitoring platforms is transforming patient diagnosis and treatment.
The market remains moderately consolidated, with leading players focusing on innovation, strategic partnerships, and global expansion to strengthen competitive positioning.
North America leads with a 41.2% share, followed by Europe at 27.6% and Asia-Pacific at 21.4%, while the insomnia segment dominates with 56.8% of the total market share.
Market Segmentation Analysis:
By Disorder
The insomnia segment dominated the sleep disorder market in 2024, accounting for a 56.8% share. Its dominance stems from the rising prevalence of stress-related sleep issues and lifestyle disorders globally. Growing awareness and diagnosis rates have led to higher prescription volumes for sleep aids. Additionally, advancements in behavioral therapies and novel drug formulations are expanding treatment accessibility. Increasing screen time and work-related fatigue continue to elevate insomnia cases, reinforcing this segment’s leadership. In contrast, sleep apnea and restless legs syndrome show steady growth driven by improved diagnostic coverage.
For instance, As of May 2022, Sleepio had been evaluated in 28 studies, including 12 RCTs, which confirmed its effectiveness for reducing insomnia.
By Product
The therapeutics segment held the largest share of 63.2% in 2024, driven by the rising use of therapeutic devices and cognitive behavioral therapy. Continuous Positive Airway Pressure (CPAP) devices remain a preferred treatment for obstructive sleep apnea. Wearable sleep aids and mobile-based behavioral programs are improving patient adherence and monitoring outcomes. Increasing healthcare expenditure and reimbursement support for non-invasive devices further boost this category. Diagnostic devices such as polysomnography and actigraphy systems are gaining traction, but their adoption is limited to clinical environments, keeping therapeutics as the dominant revenue contributor.
For instance, according to recent investor presentations in the second half of 2025, ResMed’s AirView remote monitoring ecosystem is used to monitor over 33 million patients, while the number of cloud-connectable devices in the market has surpassed 30 million.
By End-user
Hospitals and sleep laboratories led the market with a 58.4% share in 2024. Their dominance is attributed to advanced diagnostic infrastructure and the availability of multidisciplinary care for complex sleep disorders. These facilities offer comprehensive polysomnography, respiratory polygraph, and actigraphy testing under medical supervision. The segment also benefits from increasing patient referrals and insurance coverage for diagnostic procedures. Meanwhile, home care settings are expanding rapidly, supported by the adoption of portable monitoring devices and telemedicine-based therapy. The shift toward at-home diagnostics is enhancing convenience and reducing hospital load, driving balanced growth across both settings.
Key Growth Drivers
Rising Prevalence of Sleep-Related Disorders
The growing global prevalence of sleep disorders, including insomnia, sleep apnea, and narcolepsy, is a major market driver. Sedentary lifestyles, prolonged screen exposure, and increasing stress levels are causing chronic sleep deprivation. According to the World Sleep Society, more than 45% of the world’s population experiences sleep-related issues, highlighting the growing need for diagnosis and treatment. This surge in patient population is accelerating demand for therapeutic devices, behavioral therapies, and medications, driving consistent revenue growth across healthcare and homecare settings.
For instance, SomnoMed confirms more than 1,000,000 patients treated with oral appliance therapy to date.
Technological Advancements in Diagnostics and Therapeutics
Rapid innovation in sleep disorder diagnostics and therapeutic solutions is transforming patient care. AI-enabled wearable trackers, smart sleep monitoring systems, and portable polysomnography devices allow early detection and continuous monitoring. Therapeutic devices such as adaptive servo-ventilation systems and CPAP technologies are improving compliance and treatment outcomes. Integration of mobile applications and telemedicine platforms enhances patient engagement and accessibility. These innovations reduce diagnostic costs, expand remote care adoption, and create new revenue streams for manufacturers and healthcare providers.
For instance, ResMed found PAP adherence at 87% with myAir plus AirView, versus 70% with AirView alone.
Increasing Awareness and Healthcare Spending
Rising awareness about sleep health and its impact on mental and physical wellbeing is boosting demand for diagnosis and treatment. Governments and organizations are conducting campaigns to address untreated sleep disorders. Growing healthcare spending, especially in developed economies, supports the availability of advanced diagnostic centers and therapeutic devices. Insurance coverage for sleep apnea treatments and behavioral therapies is further driving adoption. Expanding patient education initiatives are encouraging individuals to seek professional help, fostering market growth across both clinical and home-based care models.
Key Trends & Opportunities
Expansion of Digital Sleep Solutions
Digital transformation in healthcare is creating new opportunities for virtual sleep management. Wearable technology and smartphone-based applications are being integrated with cloud-based analytics to monitor sleep quality. These platforms enable real-time data sharing between patients and physicians, improving treatment personalization. Companies are focusing on software-driven behavioral therapies and AI-supported sleep tracking. The rising popularity of telehealth consultations and subscription-based sleep improvement programs is widening access and creating recurring revenue opportunities for technology-driven healthcare firms.
For instance, Calm has approximately 4.5 million subscribers to its sleep and mindfulness app.
Growing Adoption of Home Sleep Testing Devices
Home-based sleep testing devices are gaining traction as patients seek convenience and cost-effective solutions. Miniaturized and wireless diagnostic tools such as portable respiratory polygraphs and actigraphy systems are driving adoption in home settings. These devices reduce waiting times for laboratory testing and enable continuous monitoring over multiple nights. Rising consumer interest in self-monitoring, coupled with expanding e-commerce distribution, supports the demand surge. Manufacturers offering user-friendly, FDA-approved home testing kits are expected to capture a larger share in this evolving market segment.
For instance, ZOLL Itamar’s WatchPAT 300 holds FDA clearance K180775 and is indicated from age 12; using total sleep time helps avoid up to 20% misclassification reported with recording time.
Integration of AI and Predictive Analytics
The use of artificial intelligence and predictive analytics in sleep medicine is opening new frontiers for data-driven diagnosis and treatment. AI algorithms analyze patient data to identify sleep patterns, predict apnea episodes, and suggest tailored therapy adjustments. Predictive systems also help in early identification of chronic conditions linked to sleep deprivation, such as cardiovascular or metabolic disorders. Healthcare providers leveraging AI-supported platforms achieve improved clinical accuracy and patient compliance, positioning technology as a central enabler of personalized sleep care.
Key Challenges
High Cost of Diagnostic and Therapeutic Devices
The elevated cost of diagnostic procedures and therapeutic devices remains a major challenge. Sleep studies conducted in laboratories involve expensive equipment like polysomnography systems and require trained specialists, increasing overall healthcare costs. Similarly, CPAP and advanced ventilation devices demand significant upfront investment. These financial barriers limit access, particularly in low-income regions, where reimbursement coverage is limited. The high price of sleep-related therapies continues to restrict mass adoption, despite increasing global awareness of the importance of sleep health.
Limited Awareness and Underdiagnosis in Developing Regions
Underdiagnosis and lack of awareness in emerging economies hinder market growth. Many individuals experiencing sleep-related symptoms do not seek medical attention due to social stigma or limited healthcare accessibility. The shortage of certified sleep specialists and diagnostic centers further compounds the problem. Insufficient public health initiatives and low prioritization of sleep medicine in healthcare programs delay early intervention. This knowledge gap results in untreated conditions, reducing patient outcomes and restricting the market’s potential expansion across developing countries.
Regional Analysis
North America
North America dominated the sleep disorder market in 2024 with a 41.2% share. The region’s leadership is driven by high awareness of sleep health, advanced healthcare infrastructure, and significant adoption of diagnostic and therapeutic devices. The United States contributes the majority of regional revenue due to strong insurance coverage and growing cases of sleep apnea and insomnia. Continuous innovation in wearable devices and home-based sleep testing further supports growth. The presence of leading manufacturers and sleep centers ensures sustained regional expansion through early diagnosis and technologically advanced treatments.
Europe
Europe accounted for a 27.6% share of the global sleep disorder market in 2024. The region benefits from an expanding network of sleep laboratories and increasing government initiatives promoting mental and sleep health. Countries such as Germany, the United Kingdom, and France lead adoption due to strong healthcare systems and favorable reimbursement policies. Growing awareness of sleep-related comorbidities like hypertension and obesity fuels diagnostic demand. The introduction of digital sleep monitoring platforms and smart therapeutic devices supports steady regional growth, with rising collaborations between healthcare providers and device manufacturers.
Asia-Pacific
Asia-Pacific captured a 21.4% share in 2024 and is expected to record the fastest growth rate through 2032. Rising stress levels, changing work patterns, and growing urbanization are increasing sleep disorder prevalence across China, Japan, India, and South Korea. Expanding healthcare access and the emergence of telemedicine are boosting diagnosis and therapy adoption. Investments in sleep clinics and low-cost wearable devices are supporting market penetration. Increasing research on sleep-related diseases and rising disposable incomes contribute to strong market momentum, making Asia-Pacific a key growth region for both diagnostics and therapeutics.
Latin America
Latin America held a 6.3% share of the global market in 2024. Growing awareness of sleep health, coupled with gradual improvements in healthcare infrastructure, is driving adoption of sleep disorder diagnostics. Brazil and Mexico are leading markets due to the expansion of urban healthcare facilities and higher diagnosis rates of sleep apnea. Economic development and government programs focused on chronic disease prevention further encourage growth. However, limited access to specialized sleep centers and affordability challenges continue to restrict market potential, although rising telehealth adoption is expected to improve accessibility.
Middle East & Africa
The Middle East & Africa accounted for a 3.5% share of the sleep disorder market in 2024. Market growth is supported by increasing recognition of sleep disorders as a public health issue and the establishment of specialized sleep clinics in Gulf Cooperation Council countries. The region is witnessing gradual adoption of portable diagnostic devices and CPAP systems. Rising healthcare investments in Saudi Arabia, the UAE, and South Africa are improving diagnosis and treatment availability. Despite limited awareness in rural areas, urban centers are driving regional demand through expanding hospital-based sleep management services.
Market Segmentations:
By Disorder
Restless Legs Syndrome
Narcolepsy
Insomnia
Sleep Apnea
Obstructive Sleep Apnea
Central Sleep Apnea
Complex Sleep Apnea
By Product
Diagnostics
Actigraphy Systems
Polysomnography Devices
Respiratory Polygraph
Sleep Screening Devices
Pulse Oximeter
Wearables
Therapeutics
Cognitive Behavioural Therapy
Therapeutic Devices
By End-user
Hospitals & Sleep Laboratories
Home Care Settings & Individuals
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
The Sleep Disorder Market features key players such as ResMed, Koninklijke Philips N.V., Fisher & Paykel Healthcare, Oura Health, Fitbit I, Natus Medical, Nihon Kohden, LivaNova, WEINMANN Emergency Medical Technology GmbH + Co. KG, Teleflex, BMC Medical, Drive DeVilbiss International, Sleep Shepherd, Sleepace, Cadwell Laboratories, Asahi Kasei Corporation, Apple Inc., Oxysleep Maxcare, Avadel, and Eli Lilly. The market is highly competitive, driven by technological innovation and strong research capabilities. Companies are focusing on developing advanced diagnostic tools, AI-driven sleep monitoring devices, and therapeutic solutions that enhance patient comfort and compliance. Strategic collaborations with healthcare providers, expansion into emerging economies, and product diversification are key growth strategies. The competition is also shaped by the integration of wearable technologies and digital sleep platforms, improving accessibility and treatment accuracy. Continuous investment in R&D, digital transformation, and personalized therapy solutions ensures sustained competitiveness across global markets.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
WEINMANN Emergency Medical Technology GmbH + Co. KG
Teleflex
BMC Medical
Drive DeVilbiss International
Sleep Shepherd
Sleepace
Cadwell Laboratories
Asahi Kasei Corporation
Apple Inc.
Oxysleep Maxcare
Avadel
Eli Lilly
Recent Developments
In 2025, Eli Lilly launched Mounjaro (tirzepatide) in India for treating type 2 diabetes and obesity
In 2024, Avadel received FDA approval for Lumryz to treat cataplexy or excessive daytime sleepiness (EDS) in pediatric patients aged 7 years and older with narcolepsy.
In 2022, Oxysleep Maxcare launched an exclusive centre for sleep disorders and Respiratory care with rehabilitation facilities.
Report Coverage
The research report offers an in-depth analysis based on Disorder, Product, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The market will witness strong growth driven by rising global sleep disorder prevalence.
Technological innovation in wearable and home-based diagnostics will enhance early detection.
Increasing adoption of AI-enabled sleep monitoring systems will improve personalized therapy outcomes.
Expansion of telemedicine platforms will make sleep treatments more accessible to remote patients.
Growing public health initiatives will raise awareness about the importance of sleep wellness.
Behavioral therapies and non-drug interventions will gain preference over traditional sedatives.
Partnerships between device makers and healthcare providers will accelerate digital health integration.
Emerging markets in Asia-Pacific and Latin America will show faster adoption of affordable solutions.
Advancements in cognitive behavioral therapy will strengthen non-invasive treatment options.
Regulatory focus on patient safety and data accuracy will drive innovation and clinical reliability.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
3. Executive Summary
4. Introduction
4.1. Overview
4.2. Key Industry Trends
5. Global Sleep Disorder Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast
12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
13. Price Analysis
14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. ResMed
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Koninklijke Philips N.V.
14.3.3. Fisher & Paykel Healthcare
14.3.4. Oura Health
14.3.5. Fitbit I
14.3.6. Natus Medical
14.3.7. Nihon Kohden
14.3.8. LivaNova
14.3.9. WEINMANN Emergency Medical Technology GmbH + Co. KG
14.3.10. Teleflex
14.3.11. BMC Medical
14.3.12. Drive DeVilbiss International
14.3.13. Sleep Shepherd
14.3.14. Sleepace
14.3.15. Cadwell Laboratories
14.3.16. Asahi Kasei Corporation
14.3.17. Apple Inc.
14.3.18. Oxysleep Maxcare
14.3.19. Avadel
14.3.20. Eli Lilly
15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for Sleep Disorder Market, and what is its projected size in 2032?
The Sleep Disorder Market was valued at USD 27.63 Billion in 2024 and is projected to reach USD 60.23 Billion by 2032.
At what Compound Annual Growth Rate is the Sleep Disorder Market projected to grow between 2025 and 2032?
The market is projected to grow at a CAGR of 10.23% during the forecast period.
Which Sleep Disorder Market segment held the largest share in 2024?
The insomnia segment held the largest share in 2024, accounting for 56.8% of the total market.
What are the primary factors fueling the growth of the Sleep Disorder Market?
Rising prevalence of insomnia and sleep apnea, growing use of wearable sleep monitors, and technological advancements in diagnostics and therapeutics drive growth.
Who are the leading companies in the Sleep Disorder Market?
Leading companies include ResMed, Koninklijke Philips N.V., Fisher & Paykel Healthcare, Oura Health, and Fitbit I.
Which region commanded the largest share of the Sleep Disorder Market in 2024?
North America commanded the largest share in 2024, accounting for 41.2% of the global market.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Sleep Disorders Treatment Drugs Market size was valued at USD 28.34 Billion in 2024 and is anticipated to reach USD 71.69 Billion by 2032, at a CAGR of 12.3% during the forecast period.
Russia Monoclonal Antibodies Market size was valued at USD 970.5 million in 2024 and is anticipated to reach USD 1,546.83 million by 2032, at a CAGR of 6% during the forecast period.
The Smart Drug Delivery Systems Market size was valued at USD 12.66 billion in 2024 and is anticipated to reach USD 53.72 billion by 2032, at a CAGR of 19.8% during the forecast period.
Glucomannan market size was valued USD 114.75 million in 2024 and is anticipated to reach USD 201.97 million by 2032, at a CAGR of 8.1% during the forecast period.
The glucosinolates market size was valued at USD 239.75 million in 2024 and is anticipated to reach USD 306.15 million by 2032, at a CAGR of 3.6% during the forecast period.
The GCC Medical Tourism Market size was valued at USD 347.71 million in 2018 to USD 367.41 million in 2024 and is anticipated to reach USD 889.97 million by 2032, at a CAGR of 10.26% during the forecast period.
The rigid endoscopes market size was valued at USD 8.2 billion in 2024 and is anticipated to reach USD 13.99 billion by 2032, at a CAGR of 6.91% during the forecast period.
The Global Pharmaceutical Packaging Market size was valued at USD 1,29,838.2 million in 2018 to USD 1,76,976.7 million in 2024 and is anticipated to reach USD 3,88,236.7 million by 2032, at a CAGR of 10.39% during the forecast period.
The Global Endoscopic Accessories Market size was valued at USD 2,464.46 million in 2018 to USD 3,553.11 million in 2024 and is anticipated to reach USD 5,975.86 million by 2032, at a CAGR of 6.25% during the forecast period.
The Global Encephalitis Treatment Market size was valued at USD 14,363.50 million in 2018 to USD 21,736.03 million in 2024 and is anticipated to reach USD 34,582.10 million by 2032, at a CAGR of 5.56% during the forecast period.
The Global EMG Biosensors Market size was valued at USD 384.92 million in 2018 to USD 687.99 million in 2024 and is anticipated to reach USD 1,479.22 million by 2032, at a CAGR of 9.35% during the forecast period.
Cord Blood Banking Market size was valued USD 27.29 billion in 2024 and is anticipated to reach USD 47.59 billion by 2032, at a CAGR of 7.2% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
